Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOPHER JOHN SAYED

Allopathic & Osteopathic Physicians Dermatology

NPI
1225265903
CMS profile
1302035
Location
CHAPEL HILL, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$94,039.05

91 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $81,775.20 77
UCB SA $4,099.00 5
Incyte Corporation $2,522.45 3
UCB, Inc. $2,190.00 2
Novartis Pharmaceuticals Corporation $2,102.40 3
Novartis Pharma AG $1,350.00 1

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOPHER JOHN SAYED

NPI 1225265903 · CMS profile ID 1302035

Allopathic & Osteopathic Physicians / Dermatology

CHAPEL HILL, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1225265903?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOPHER JOHN SAYED, NPI 1225265903, CMS profile ID 1302035. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225265903?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHRISTOPHER JOHN SAYED, NPI 1225265903, CMS profile ID 1302035. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225265903?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHRISTOPHER JOHN SAYED, NPI 1225265903, CMS profile ID 1302035, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1225265903?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

91 matching records · $94,039.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 91 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–91 of 91.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $2,500.0006/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841229 CMS
AbbVie Inc. $2,500.0006/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841225 CMS
AbbVie Inc. $29.2006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841221 CMS
AbbVie Inc. $37.9906/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841217 CMS
AbbVie Inc. $9.6306/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841213 CMS
AbbVie Inc. $3,500.0006/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841209 CMS
AbbVie Inc. $1,108.9405/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841201 CMS
AbbVie Inc. $111.1105/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841205 CMS
AbbVie Inc. $2,500.0005/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841197 CMS
AbbVie Inc. $20.4305/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841193 CMS
AbbVie Inc. $49.1305/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841189 CMS
UCB SA $590.0005/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021299018 CMS
UCB SA $590.0005/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021299025 CMS
UCB SA $649.0005/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021299031 CMS
AbbVie Inc. $2,500.0004/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841185 CMS
AbbVie Inc. $16.6204/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841181 CMS
AbbVie Inc. $1,500.0003/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841179 CMS
AbbVie Inc. $41.9203/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841163 CMS
AbbVie Inc. $44.5403/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841167 CMS
AbbVie Inc. $27.5103/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841171 CMS
AbbVie Inc. $49.7803/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841175 CMS
AbbVie Inc. $750.0003/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841159 CMS
AbbVie Inc. $2,500.0003/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841155 CMS
AbbVie Inc. $29.4003/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841153 CMS
AbbVie Inc. $2,500.0002/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841149 CMS
AbbVie Inc. $2,500.0002/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841145 CMS
AbbVie Inc. $29.4402/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841141 CMS
AbbVie Inc. $125.0002/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841133 CMS
AbbVie Inc. $2,500.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841137 CMS
AbbVie Inc. $30.5802/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841129 CMS
AbbVie Inc. $22.1501/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841121 CMS
AbbVie Inc. $53.0301/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841127 CMS
AbbVie Inc. $2,500.0001/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841117 CMS
AbbVie Inc. $3,500.0001/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841113 CMS
AbbVie Inc. $335.7501/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841109 CMS
AbbVie Inc. $120.0701/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841093 CMS
AbbVie Inc. $285.9201/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841097 CMS
AbbVie Inc. $492.8801/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841101 CMS
AbbVie Inc. $677.8001/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841105 CMS
AbbVie Inc. $36.2501/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998841089 CMS
UCB SA $1,770.0001/05/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021299039 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $68,089.98 63
PY2020 $38,190.60 26
PY2021 $78,642.22 71
PY2022 $89,997.71 76
PY2023 $94,039.05 91
PY2024 $165,952.41 104
PY2025 $155,311.90 84

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,200.00 1
PY2025 Principal investigator $1,208,339.48 198
PY2024 Recipient $400.00 1
PY2024 Principal investigator $237,785.03 245
PY2023 Recipient $324.09 1
PY2023 Principal investigator $212,348.72 39
PY2022 Principal investigator $463,530.67 14
PY2021 Principal investigator $383,744.60 30
PY2020 Principal investigator $20,125.24 5
PY2019 Principal investigator $89,935.36 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

199 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $540.00 12/18/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240605778
Principal investigator 1 Incyte Corporation $84.00 12/18/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240605785
Principal investigator 1 Incyte Corporation $435.00 12/18/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605789
Principal investigator 1 Incyte Corporation $41.00 12/18/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605798
Principal investigator 1 Incyte Corporation $77.00 12/18/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605832
Principal investigator 1 Incyte Corporation $50.00 12/11/2025 Covered Recipient Teaching Hospital
University Of North Carolina Hosp.
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240492608
Principal investigator 1 Incyte Corporation $44.00 12/11/2025 Covered Recipient Teaching Hospital
University Of North Carolina Hosp.
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240492614
Principal investigator 1 Incyte Corporation $300.00 12/11/2025 Covered Recipient Teaching Hospital
University Of North Carolina Hosp.
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240492620
Principal investigator 1 Incyte Corporation $245.00 12/11/2025 Covered Recipient Teaching Hospital
University Of North Carolina Hosp.
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240492626
Principal investigator 1 Incyte Corporation $396.00 12/11/2025 Covered Recipient Teaching Hospital
University Of North Carolina Hosp.
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240492631
Principal investigator 1 Incyte Corporation $2,919.30 12/08/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605810
Principal investigator 1 Incyte Corporation $1,391.40 12/04/2025 Covered Recipient Teaching Hospital
University Of North Carolina Hosp.
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240492599
Principal investigator 1 Incyte Corporation $154.60 12/04/2025 Covered Recipient Teaching Hospital
University Of North Carolina Hosp.
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240492603
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605781
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605814
Principal investigator 1 Incyte Corporation $78.21 12/01/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605844
Principal investigator 1 Incyte Corporation $84.00 12/01/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605860
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605891
Principal investigator 1 Incyte Corporation $435.00 12/01/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605908
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605923
Principal investigator 1 Incyte Corporation $1,568.00 11/24/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605818
Principal investigator 1 Incyte Corporation $1,158.10 11/24/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605838
Principal investigator 1 Incyte Corporation $7,930.00 11/19/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605793
Principal investigator 1 Incyte Corporation $1,231.00 11/19/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605829
Principal investigator 1 Incyte Corporation $51.00 11/19/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605867
Principal investigator 1 Incyte Corporation $64.00 11/19/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605888
Principal investigator 1 Incyte Corporation $435.00 11/19/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605899
Principal investigator 1 Incyte Corporation $435.00 11/19/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605903
Principal investigator 1 Incyte Corporation $41.00 11/19/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605911
Principal investigator 1 Incyte Corporation $1,231.00 11/07/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605774
Principal investigator 1 Incyte Corporation $435.00 11/07/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605807
Principal investigator 1 Incyte Corporation $100.00 11/07/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605835
Principal investigator 1 Incyte Corporation $1,641.00 11/05/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240605803
Principal investigator 1 Incyte Corporation $924.00 11/05/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240605856
Principal investigator 1 Incyte Corporation $3,500.00 11/05/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240605873
Principal investigator 1 Incyte Corporation $396.00 11/05/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240605877
Principal investigator 1 Incyte Corporation $20,000.00 11/05/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240605920
Principal investigator 1 Incyte Corporation $5,313.00 11/05/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240605927
Principal investigator 1 Incyte Corporation $2,291.00 10/20/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605825
Principal investigator 1 Incyte Corporation $929.00 10/20/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605869
Principal investigator 1 Incyte Corporation $1,568.00 10/20/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605915
Principal investigator 1 Incyte Corporation $100.00 10/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605841
Principal investigator 1 Incyte Corporation $7,930.00 10/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605863
Principal investigator 1 Incyte Corporation $435.00 10/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605881
Principal investigator 1 Incyte Corporation $42.00 10/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605884
Principal investigator 1 Incyte Corporation $1,903.50 10/08/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605895
Principal investigator 1 Incyte Corporation $292.00 10/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605849
Principal investigator 1 Incyte Corporation $365.00 10/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605853
Principal investigator 1 Incyte Corporation $435.00 09/17/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605710
Principal investigator 1 Incyte Corporation $41.00 09/17/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605714
Principal investigator 1 Incyte Corporation $115.00 09/17/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605717
Principal investigator 1 Incyte Corporation $435.00 09/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605762
Principal investigator 1 Incyte Corporation $1,903.50 09/10/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605705
Principal investigator 1 Incyte Corporation $41.00 09/05/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605676
Principal investigator 1 Incyte Corporation $435.00 09/05/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605683
Principal investigator 1 Incyte Corporation $141.00 09/05/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605757
Principal investigator 1 Incyte Corporation $435.00 09/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605690
Principal investigator 1 Incyte Corporation $115.00 09/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605694
Principal investigator 1 Incyte Corporation $41.00 09/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605754
Principal investigator 1 Incyte Corporation $32.88 09/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605619
Principal investigator 1 Incyte Corporation $32.88 09/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605622
Principal investigator 1 Incyte Corporation $137.40 09/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605722
Principal investigator 1 Incyte Corporation $8.48 09/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605726
Principal investigator 1 Incyte Corporation $32.88 09/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605730
Principal investigator 1 Incyte Corporation $109.52 09/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605736
Principal investigator 1 Incyte Corporation $541.60 09/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605741
Principal investigator 1 Incyte Corporation $64.72 09/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605744
Principal investigator 1 Incyte Corporation $49.36 09/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605750
Principal investigator 1 Incyte Corporation $32.88 09/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605770
Principal investigator 1 Incyte Corporation $42.00 08/22/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605633
Principal investigator 1 Incyte Corporation $435.00 08/22/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605637
Principal investigator 1 Incyte Corporation $1,809.60 08/20/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605641
Principal investigator 1 Incyte Corporation $1,461.00 08/20/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605654
Principal investigator 1 Incyte Corporation $1,232.00 08/01/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605686
Principal investigator 1 Incyte Corporation $1,540.00 08/01/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605766
Principal investigator 1 Incyte Corporation $1,231.00 07/28/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605630
Principal investigator 1 Incyte Corporation $100.00 07/28/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605668
Principal investigator 1 Incyte Corporation $1,314.90 07/18/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605700
Principal investigator 1 Incyte Corporation $281.00 07/09/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605646
Principal investigator 1 Incyte Corporation $1,540.00 07/09/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605650
Principal investigator 1 Incyte Corporation $128.00 07/09/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605660
Principal investigator 1 Incyte Corporation $435.00 07/09/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605663
Principal investigator 1 Incyte Corporation $42.00 07/07/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605628
Principal investigator 1 Incyte Corporation $435.00 07/07/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605672
Principal investigator 1 Incyte Corporation $2,173.00 06/25/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605453
Principal investigator 1 Incyte Corporation $1,097.60 06/25/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605615
Principal investigator 1 Incyte Corporation $435.00 06/11/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605470
Principal investigator 1 Incyte Corporation $100.00 06/11/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605478
Principal investigator 1 Incyte Corporation $1,232.00 06/11/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605552
Principal investigator 1 Incyte Corporation $1,540.00 06/11/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605559
Principal investigator 1 Incyte Corporation $42.00 06/11/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605604
Principal investigator 1 Incyte Corporation $19.57 06/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605527
Recipient Novartis Pharma AG $1,200.00 05/28/2025 Covered Recipient Physician LOU064J12301 and LOU064J12302 No dispute reported 06/30/2026 1248171940
Principal investigator 1 Incyte Corporation $435.00 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605389
Principal investigator 1 Incyte Corporation $1,568.00 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605431
Principal investigator 1 Incyte Corporation $104.00 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605438
Principal investigator 1 Incyte Corporation $1,393.20 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605442
Principal investigator 1 Incyte Corporation $1,231.00 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605447
Principal investigator 1 Incyte Corporation $186.88 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605450
Principal investigator 1 Incyte Corporation $42.00 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605458
Principal investigator 1 Incyte Corporation $42.00 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605462
Principal investigator 1 Incyte Corporation $60.00 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605465
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605484
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605489
Principal investigator 1 Incyte Corporation $62.27 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605493
Principal investigator 1 Incyte Corporation $12.15 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605497
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605501
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605504
Principal investigator 1 Incyte Corporation $2.12 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605507
Principal investigator 1 Incyte Corporation $24.68 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605511
Principal investigator 1 Incyte Corporation $80.15 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605515
Principal investigator 1 Incyte Corporation $48.54 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605519
Principal investigator 1 Incyte Corporation $24.68 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605523
Principal investigator 1 Incyte Corporation $16.18 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605531
Principal investigator 1 Incyte Corporation $0.31 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605548
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605564
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605569
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605575
Principal investigator 1 Incyte Corporation $8.22 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605579
Principal investigator 1 Incyte Corporation $435.00 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605596
Principal investigator 1 Incyte Corporation $80.15 05/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605608
Principal investigator 1 Incyte Corporation $435.00 04/25/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605400
Principal investigator 1 Incyte Corporation $90.00 04/25/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605410
Principal investigator 1 Incyte Corporation $141.00 04/25/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605421
Principal investigator 1 Incyte Corporation $435.00 04/25/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605427
Principal investigator 1 Incyte Corporation $41.00 04/25/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605583
Principal investigator 1 Incyte Corporation $41.00 04/25/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605592
Principal investigator 1 Incyte Corporation $167.00 04/16/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605406
Principal investigator 1 Incyte Corporation $435.00 04/16/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605414
Principal investigator 1 Incyte Corporation $41.00 04/16/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605424
Principal investigator 1 Incyte Corporation $2,115.00 04/09/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605434
Principal investigator 1 Incyte Corporation $866.50 04/09/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605535
Principal investigator 1 Incyte Corporation $1,540.00 04/09/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605540
Principal investigator 1 Incyte Corporation $1,540.00 04/09/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605544
Principal investigator 1 Incyte Corporation $1,568.00 04/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605392
Principal investigator 1 Incyte Corporation $1,012.00 04/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605395
Principal investigator 1 Incyte Corporation $26.78 04/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605473
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605481
Principal investigator 1 Incyte Corporation $1,461.00 04/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605599
Principal investigator 1 Incyte Corporation $1,511.10 03/12/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605159
Principal investigator 1 Incyte Corporation $365.00 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605202
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605281
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605299
Principal investigator 1 Incyte Corporation $4.24 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605302
Principal investigator 1 Incyte Corporation $45.80 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605306
Principal investigator 1 Incyte Corporation $186.81 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605310
Principal investigator 1 Incyte Corporation $14.58 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605322
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605326
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605329
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605334
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605338
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605342
Principal investigator 1 Incyte Corporation $0.62 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605347
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605350
Principal investigator 1 Incyte Corporation $12.86 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605357
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605370
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605374
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605378
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605382
Principal investigator 1 AstraZeneca Pharmaceuticals LP $238,718.30 02/17/2025 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA RESEARCH
An open label prospective study of Anifrolumab for the treatment of hidradenitis suppurativa No dispute reported 06/30/2026 1185555511
Principal investigator 1 Incyte Corporation $2,115.00 02/10/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605211
Principal investigator 1 Incyte Corporation $1,299.60 02/10/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605224
Principal investigator 1 Incyte Corporation $435.00 02/07/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605207
Principal investigator 1 Incyte Corporation $42.00 02/07/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605216
Principal investigator 1 Incyte Corporation $1,305.00 02/07/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605220
Principal investigator 1 Incyte Corporation $141.00 02/07/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605228
Principal investigator 1 Incyte Corporation $41.00 02/07/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605232
Principal investigator 1 AstraZeneca Pharmaceuticals LP $769,370.40 01/29/2025 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA RESEARCH
An open label prospective study of Anifrolumab for the treatment of hidradenitis suppurativa No dispute reported 06/30/2026 1185555513
Principal investigator 1 Incyte Corporation $1,411.20 01/27/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605182
Principal investigator 1 Incyte Corporation $1,627.00 01/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605162
Principal investigator 1 Incyte Corporation $1,665.00 01/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605165
Principal investigator 1 Incyte Corporation $1,314.90 01/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605169
Principal investigator 1 Incyte Corporation $1,627.00 01/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605190
Principal investigator 1 Incyte Corporation $740.10 01/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605198
Principal investigator 1 Incyte Corporation $1,540.00 01/15/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605366
Principal investigator 1 Incyte Corporation $54.00 01/08/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605173
Principal investigator 1 Incyte Corporation $435.00 01/08/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605177
Principal investigator 1 Incyte Corporation $269.00 01/08/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605186
Principal investigator 1 Incyte Corporation $123.00 01/08/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605194
Principal investigator 1 UCB SA $68,785.72 01/03/2025 Non-covered Recipient Entity
University of North Carolina at Chapel Hill
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246657520
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605235
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605239
Principal investigator 1 Incyte Corporation $217.30 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605242
Principal investigator 1 Incyte Corporation $148.40 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605246
Principal investigator 1 Incyte Corporation $190.80 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605250
Principal investigator 1 Incyte Corporation $47.70 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605256
Principal investigator 1 Incyte Corporation $196.10 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605264
Principal investigator 1 Incyte Corporation $84.80 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605268
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605272
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605275
Principal investigator 1 Incyte Corporation $159.00 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605278
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605287
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605291
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605295
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605314
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605317
Principal investigator 1 Incyte Corporation $5.38 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605354
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605362
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
UNC DERMATOLOGY AND SKIN CANCER CENTER AT SOUTHERN VILLAGE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240605386